Blog
Norwegian data protection authority strongly recommends synthetic data for software testing
By Dr. Khaled El Emam Posted On: December 2nd, 2021
Blog
What industry can learn from RWE demonstration projects
As global regulatory and health technology assessment (HTA) bodies continue to iterate on ...
Blog
RWE guidance watch: EMA real world evidence guidance on registry-based studies
UPDATE: As of November 2021, EMA has now issued its final guideline on registry-based ...
Blog
New Gartner survey suggests synthetic data is the future of data sharing
By Dr. Khaled El Emam Posted On: November 9th, 2021
Blog
COVID-19 vaccine rollout shows real-world evidence was ready for the spotlight
Just 10 months since administration of the first COVID-19 vaccine dose, hundreds of ...
Blog
Join primary and real-world data to generate patient-relevant RWE across the product lifecycle: Q&A with Dr. Javier Jimenez of Syneos Health
Understanding how medical interventions impact patients has always been a top priority ...
Blog
Ten Recommendations for Regulating Non-identifiable Data
There is considerable activity today in regulatory development and updates around the ...
Blog
ICPE Research Spotlight 2021: Part II: Forging methods to advance principled database epidemiology
This year at ICPE All Access, Aetion’s scientific research was represented across ...
Blog
ICPE Research Spotlight 2021: Part I: Findings from Aetion-FDA research collaboration to advance understanding of COVID-19 with RWE
This year at ICPE All Access, Aetion’s scientific research is represented across ...
Blog
RWE to inform value decision-making: Learnings from ICER’s 24-month reassessment pilot
In its 2020 Value Assessment Framework, the Institute of Clinical and Economic Review ...
Blog
Patient voice in RWE: Generating evidence that will impact payer and HTA decision-making
With the rise of patient-centered medicine and accelerated approvals, health technology ...
Blog
RWE Guidance Watch: IMPACT HTA publishes recommendations on the use of RWE in HTA
As researchers await comprehensive guidance on the use of real-world evidence (RWE)—and ...
Blog
An update on efforts to standardize and democratize RWE: Q&A with Dr. Nirosha Mahendraratnam Lederer
As real-world evidence (RWE) adoption continues to ramp up across health care, ...
Blog
Research spotlight: Gilead Sciences and Aetion use RWE to assess the comparative effectiveness of remdesivir for COVID-19
As COVID-19 continues to evolve, frontline health care workers are eager for real-world ...
Blog
Using RWE to characterize diseases as novel treatments become available: Q&A with Dr. Maria Schneeweiss
As novel therapies come to market, especially in disease areas that aren’t as well ...
Blog
Research spotlight: Using RWD sources to describe the patient burden of a poorly understood rare disease
This month, Aetion and Boehringer Ingelheim published two co-authored papers which ...
Blog
Research spotlight: Organized structure of RWE best practices
In the last five to 10 years, stakeholders from around the globe have launched ...
Blog
How NICE is approaching guidelines for RWE generation: Q&A with Dr. Páll Jónsson
In its recently announced five-year strategy, the UK’s National Institute for Health and ...
Blog
Introducing the RWE Alliance: How a cross-industry coalition aims to advance RWE policy
The last several years have been foundational in the effort to advance the use of ...
Blog
How leading-edge teams are using RWE to accelerate drug development: A conversation with Janssen R&D and Sanofi
The majority of biopharma organizations are investing in real-world evidence (RWE) ...
Blog
How payers and providers can leverage RWE: Q&A with Bill Guptail, SVP of Value-Based Care, Aetion
As payers and providers continue to navigate value-based agreements and strive to improve ...
Blog
How using an RWE platform can support building regulatory-grade ECAs
An external control arm (ECA) study is a cutting-edge pharmacoepidemiologic design that ...
Blog
RWE plays an integral role in NICE’s five-year strategy
For the UK’s National Institute for Health and Care Excellence (NICE) the COVID-19 ...
Blog
How RWE can support safety in Europe: Dr. Pierre Engel on leveraging innovative strategies to meet regulatory requirements
In Europe as in the U.S., biopharma organizations, regulators, and health technology ...